CN102818892B - Detection kit for prostate specific antigen and preparation method thereof - Google Patents
Detection kit for prostate specific antigen and preparation method thereof Download PDFInfo
- Publication number
- CN102818892B CN102818892B CN201210291449.9A CN201210291449A CN102818892B CN 102818892 B CN102818892 B CN 102818892B CN 201210291449 A CN201210291449 A CN 201210291449A CN 102818892 B CN102818892 B CN 102818892B
- Authority
- CN
- China
- Prior art keywords
- antibody
- fitc
- solution
- fpsa
- solid phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010072866 Prostate-Specific Antigen Proteins 0.000 title claims abstract description 26
- 238000001514 detection method Methods 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 102000007066 Prostate-Specific Antigen Human genes 0.000 title abstract 2
- 239000007790 solid phase Substances 0.000 claims abstract description 28
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 22
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000758 substrate Substances 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 238000002372 labelling Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 238000013016 damping Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000007979 citrate buffer Substances 0.000 claims description 4
- 238000004020 luminiscence type Methods 0.000 claims description 4
- GCXHSBQTVXCWBK-UHFFFAOYSA-N 1,2-dichloroethylbenzene Chemical compound ClCC(Cl)C1=CC=CC=C1 GCXHSBQTVXCWBK-UHFFFAOYSA-N 0.000 claims description 3
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 claims description 3
- 239000006249 magnetic particle Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 241000872931 Myoporum sandwicense Species 0.000 claims description 2
- 229910021538 borax Inorganic materials 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 230000003139 buffering effect Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 238000003760 magnetic stirring Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 239000007974 sodium acetate buffer Substances 0.000 claims description 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical group ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 abstract description 11
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 6
- 238000003556 assay Methods 0.000 abstract description 5
- 239000011248 coating agent Substances 0.000 abstract description 3
- 238000000576 coating method Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 239000013642 negative control Substances 0.000 abstract 1
- 239000013641 positive control Substances 0.000 abstract 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 15
- 206010060862 Prostate cancer Diseases 0.000 description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 239000012744 reinforcing agent Substances 0.000 description 4
- KQDJTBPASNJQFQ-UHFFFAOYSA-N 2-iodophenol Chemical compound OC1=CC=CC=C1I KQDJTBPASNJQFQ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- ZICQBHNGXDOVJF-UHFFFAOYSA-N diamantane Chemical compound C1C2C3CC(C4)CC2C2C4C3CC1C2 ZICQBHNGXDOVJF-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- -1 pH=7.4) Substances 0.000 description 2
- 238000004375 physisorption Methods 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the field of immunoassay medicine, and specifically provides a chemiluminescence immunoassay diagnostic kit for a free prostate specific antigen (fPSA) and a preparation method thereof. The kit provided by the invention comprises an anti-FITC antibody coated solid phase vector, an FITC marked anti-PSA antibody, an enzyme marked anti-fPSA antibody, a chemiluminescent substrate acted by the above enzyme, a negative control solution and a positive control solution. The preparation method of the above kit comprises the following steps: 1) coating a solid-phase vector with the anti-FITC antibody; 2) marking the anti-PSA antibody with FITC to obtain the FITC marked anti-PSA antibody; 3) marking the anti-PSA antibody with an enzyme to obtain the enzyme marked anti-fPSA antibody; and 4) subpackaging and assembling. The kit provided by the invention has low cost and high sensitivity, and can improve sensitivity and reproducibility of the assay and reduce the usage amount of antibodies compared with an existing chemiluminescence immunoassay detection method.
Description
Technical field
The present invention relates to field of immunoassay medicine, particularly, the invention provides chemical luminescence immune analysis diagnosis reagent kit of a kind of prostate specific antigen and preparation method thereof.
Background technology
Along with the change of China's aging population, dietary structure and environmental factor, and the raising of health care level, the incidence of disease of prostate cancer in increasing trend year by year, leapt to male urinary, the 3rd of reproductive system malignant tumour.The early stage general non-evident sympton of prostate cancer, once find often to appear at late period, has missed best occasion for the treatment, therefore, has needed responsive method of early diagnosis.
Prostate specific antigen (PSA, prostate specific antigen) is the tumor markers that diagnosing prostate cancer is the most responsive clinically at present, has been acknowledged as the important indicator that prostate cancer detects and assesses, has had very high sensitivity.PSA is a kind of containing 237 amino acid whose single chain polypeptides, belongs to and has the tissue-specific serine protease having the effect of chymotrypsin sample.Mainly exist with PSA with in conjunction with state PSA in serum, free state is called fPSA, is called (tPSA) in conjunction with state; PSA has tissue specificity, but it there is no tumour-specific.Have in the prostate cancer of clinical meaning at great majority, PSA can raise, but benign prostatic hyperplasis and prostatitis also there will be the result of the PSA positive.At present, in serum, PSA level is the Grey Diagnosis district of prostate cancer between 4-10 μ g/L.In diagnosis grey area, prostate cancer (PCa) has larger overlapping region with benign prostatic hyperplasis (BPH) and prostatitis.Along with deepening continuously of studying prostatic disorders and PSA, find that in PCa patients serum, most PSA is bonding state, and f-PSA concentration level is compared with patient BPH and normal person, obviously on the low side.Therefore, the method solving this problem detects free prostate gland specificity antigen exactly, and introduces new clinical indices-Free to total PSA ratio.This is for improving the specificity of examination with the PCa of diagnosis gray area, and the false positive rate reducing clinical examination examination has great importance.
The method of current detection fPSA has a lot, labelling immunoassay technology wherein based on antibody-antigene specific reaction, as radiommunoassay, EIA enzyme immunoassay, time resolved fluoro-immunoassay and chemiluminescence immune assay etc., owing to having the advantages such as screening simple to operate, quick, to be applicable to a large amount of sample and detection, it is primary dcreening operation detection method general clinically at present.The basic theories of these ultramicron detection techniques is substantially identical, and their common feature is that sensitivity is good, high specificity; Difference is that tracer agent used and the signal that sends are different.According to a large amount of experimental results and clinical practice data, from practicality, stability, accuracy and development prospect, be followed successively by: chemiluminescence immune assay, time resolved fluoro-immunoassay, radiommunoassay and EIA enzyme immunoassay.There is shortcomings in radio immunoassay, as complicated operation, measurement result is unstable, the reagent holding time is short, radioactive contamination, expensive equipment etc., although fluoroimmunoassay and EIA enzyme immunoassay overcome alpha-contamination problem, its sensitivity is restricted.The highly sensitive chemiluminescence immune assay grown up thus is more and more subject to the favor of people.
What chemiluminescence immune analysis method was mostly applied in the principle detecting f-PSA is double antibody sandwich method, it be by PSA antibody by the method direct coated of physisorption at solid phase carrier, then removed the analysis thing or sample substrate that do not combine up by washing.This direct coated method can have some to affect on analytical parameters: (1) antigen in solid phase, can cause the inhomogeneity that antigen combines in solid phase by physisorption direct coated, therefore, poor reproducibility, incubative time is long; (2) different from the association reaction of Ag-Ab in the liquid phase, be coated on the albumen (antibody or antigen) in solid phase, its binding site is more close, therefore can cause the immunoactive portions inactivation of albumen, and activity even only reaches about 10% of coating protein amount sometimes; (3) amount being attached to antigen in solid phase is not only relevant with character such as hydrophobicity, the isoelectric point etc. of antigen self, also by the impact of the external conditions such as the preparation of antigenic solution and preservation.And HIV antigen is attached on solid phase carrier by the HIV antigen that the present invention adopts anti-FITC antibody and FITC to mark, thus overcome many shortcomings of physisorphtion direct coated HIV antigen.
In addition, chemical luminescence immune analysis reagent box major part of the prior art is closed full automatic chemiluminescence measuring system, need expensive Full-automatic chemiluminescence measuring instrument, thus limit and promote the use of, cannot effectively be widely used in clinical diagnosis and research work.
Summary of the invention
Propose to solve the problem and complete the present invention.Particularly, the invention solves the problems such as diagnostic kit homogeneity of the prior art, poor reproducibility.
The object of this invention is to provide a kind of free prostate gland specificity antigen (fPSA) chemical luminescence immune analysis diagnosis reagent kit.
Another object of the present invention is to provide a kind of method preparing mentioned reagent box.
FPSA diagnostic kit according to the present invention comprises following component:
1) solid phase carrier of anti-FITC antibody bag quilt;
2) the anti-PSA antibody of FITC mark;
3) the anti-fPSA antibody of enzyme labeling;
4) chemical luminous substrate that acts on of above-mentioned enzyme; And
5) standard items of series concentration.
Wherein, described solid phase carrier is microwell plate, plastic bead, plastic tube or magnetic-particle.Described enzyme is alkaline phosphatase or horseradish peroxidase.The chemical luminous substrate that above-mentioned enzyme acts on is (diamantane)-1,2-dichloroethane, 3-(2
'-spiral diamantane) and-4-methoxyl-4-(3 "-phosphorus acyloxy) phenyl-1,2-dichloroethane, CSPD or CDP-Star, luminol or different luminol.
Present invention also offers a kind of method preparing mentioned reagent box, the method comprises the following steps:
1) with the solid phase carrier of anti-FITC antibody bag quilt;
2) mark anti-PSA antibody with FITC, obtain the anti-PSA antibody of FITC mark;
3) with enzyme labeling anti-fPSA antibody, the anti-fPSA antibody of enzyme labeling is obtained;
4) standard items of the anti-PSA antibody of the FITC mark of the above-mentioned acquisition of packing, the anti-fPSA antibody of enzyme labeling, chemical luminous substrate that this enzyme acts on, series concentration; And
5) finished product is assembled into.
Wherein, the solid phase carrier of anti-FITC antibody bag quilt is used by the following method:
1) by bag by be added to anti-FITC antibody pH=4.4 ~ 5.0, preferably 4.8 citrate buffer solution in mix, with gained mixed liquor bag by solid phase carrier;
2) washing step 1) in the solid phase carrier of bag quilt; And
3) use bovine serum albumin(BSA) closes the solid phase carrier through washing.
According to method of the present invention, wherein, described solid phase carrier is microwell plate, plastic bead, plastic tube or magnetic-particle.Described enzyme is horseradish peroxidase or alkaline phosphatase.The chemical luminous substrate that this enzyme acts on can be (diamantane)-1,2-dichloroethane, 3-(2
'-spiral diamantane) and-4-methoxyl-4-(3 "-phosphorus acyloxy) phenyl-1,2-dichloroethane, CSPD or CDP-Star, luminol or different luminol.
Kit of the present invention can adopt following concrete form, the calf serum that it comprises the opaque microwell plate in 96 holes or 48 holes of anti-FITC antibody bag quilt, the anti-PSA antibody of FITC mark, the anti-fPSA antibody of horseradish peroxidase-labeled, series concentration standard items, calibration object matrix serum are deactivation, 20 times of concentrated cleaning solutions are the 0.02M phosphate buffer (PBS containing 0.05% Tween-20, pH=7.4), chemical luminous substrate A, B liquid is respectively luminol solution, hydrogen peroxide and special efficacy reinforcing agent (to iodophenol) solution thereof, each 1 bottle.
According to the present invention, when use two antibody system is as FITC and anti-FITC Antibody System ankyrin, the immunocompetence of immobilized antigen albumen can be preserved to a great extent.Anti-FITC antibody molecule also can in conjunction with 3 ~ 4 FITC molecules, and specificity and affinity are all very strong.Both are just very stable once combination.When FITC-anti-FITC antibody forming system is as solid phase, first pre-coated anti-FITC antibody in solid phase, PSA antibody immobilization FITC being marked by FITC-anti-FITC antibody response.This method for coating not only can increase the antigen amount on solid phase carrier, but also the binding site on antigen can be made fully to expose.Therefore, use two antibody systems as solid phase, not only can improve the sensitivity of analysis, homogeneity and reappearance, the use amount of PSA antibody can also be reduced.And the bag of anti-FITC antibody can be applied to many analysis detected objects by microwell plate as unified solid phase carrier.
Kit according to the present invention adopts two antibody systems as solid phase carrier, double-antibody sandwich pattern principle, the chemical luminous system of highly sensitive luminol-hydrogen peroxide-horseradish peroxidase and reinforcing agent thereof is as input system, establish a kind of two anti-solid state chemistry chemiluminescence immunoassay methods of highly sensitive, low cost, and be prepared into the diagnostic kit measuring blood or blood plasma Free Prostate-specific Antigen (fPSA), compared with ELISA detection kit, sensitivity improves about 100 times; Compared with existing chemiluminescence immune assay detection method, the sensitivity of analysis can be improved, homogeneity and reappearance, reduce the use amount of PSA antibody.This detection method has very high sensitivity, detects and can shift to an earlier date a couple of days diagnosis, to the early diagnosis of prostate cancer, carry out therapeutic intervention ahead of time and be of great significance than traditional enzyme-linked method.Use kit of the present invention to reduce cost, the health investment also making people limited is used more effectively.
Embodiment
Following embodiment is to explain the present invention in more detail, but should not be construed as the present invention and be confined to this.
embodiment 1 prepares fPSA chemiluminescence diagnostic kit of the present invention
FPSA diagnostic kit of the present invention comprises:
1) the luminous microwell plate in 96 holes that anti-FITC antibody is pre-coated or 48 holes;
2) the anti-PSA antibody of FITC mark;
3) the anti-fPSA antibody of horseradish peroxidase-labeled;
4) standard items of series concentration;
5) sample diluting liquid is the calf serum of deactivation;
6) 20 times of concentrated cleaning solutions are the 0.02M phosphate buffer (PBS, pH=7.4) containing 0.05% Tween-20;
7) chemical luminous substrate A, B liquid is respectively luminol solution, hydrogen peroxide and special efficacy reinforcing agent (to iodophenol) solution.
Prepare mentioned reagent box by the following method:
1, bag is added to mixing in citrate buffer solution (pH=4.8) with anti-FITC antibody, is added in luminous micropore plate hole, every hole 100 μ L, placed 15 h bag quilts for 4 DEG C.Wash after five times with cleansing solution, use ox
Seralbumin (BSA) solution room temperature closes 2 hours.Discard liquid in hole, dry ELISA Plate, sealing, namely completes the preparation of pre-coated elisa plate.
2, with direct labelling method, FITC and PSA antibody is marked, obtain the PSA antibody of FITC mark.
Direct labelling method concrete steps are as follows:
(I) A liquid: get the Na that PSA antibody 1 mg puts 50 mM pH 9.3
2cO
3-NaHCO
34 DEG C of dialysis 24 h in damping fluid, last fixing fabric structure is within 200 μ l;
(II) B liquid: get the Na that FITC (Beijing Xin Jingke biotech company) 2 mg are dissolved in 1 ml 50 mM pH 9.3
2cO
3-NaHCO
3in damping fluid;
(III) A liquid is placed in magnetic stirring apparatus, gets B liquid 25 μ l and slowly drop in A liquid, added between 5-8 minute, prevent bubble, then put 4 DEG C and stir 12-16 hour;
(IV) reactant liquor is taken out the centrifugation 20 minutes in 10000 revs/min.Removing microprecipitation thing, supernatant dress bag filter, puts in the PBS solution of 10 mM pH=7.4 and dialyses 4 days, change dislysate every day 2 times;
(V) centrifugally remove sediment, label is diluted to 1 ml, adds appropriate NaN
3, preserve at packing ， – 20 DEG C.
3, utilize the Over-voltage protection of improvement, mark fPSA antibody and horseradish peroxidase are combined, obtains the f-PSA antibody labeling thing of horseradish peroxidase-labeled.
The concrete steps of the Over-voltage protection of improvement are as follows:
(Ι) taking 2mgHRP is dissolved in 1ml distilled water;
(II) NaIO of the 0.1mol/L that 200 μ l newly configure is added
4solution, stirs 20 minutes in room temperature gently.Solution is brown-green;
(III) by sodium acetate buffer dialysed overnight at 4 DEG C of the 0.001mol/L of pH=4.4;
(IV) 20 μ l 0.2mol/L Na are added
2cO
3damping fluid, makes pH value of solution be promoted to about 9.0-9.5;
(V) with the carbonate buffer solution of 0.01mol/L, pH=9.5, fPSA antibody is deployed into the concentration of 8mg/ml.And antibody-solutions is slowly added in isopyknic above-mentioned HRP solution, stirring at room temperature 2 hours;
(VI) add the dobell's solution of the 4mg/ml of fresh configuration, be placed in 4 DEG C 2 hours;
(VII) in 4 DEG C, dialyse 24 hours in the sodium borate buffer liquid of 0.1 mol/L, exchange buffering liquid 3 times therebetween;
(VIII) add equivalent 60% neutral glycerine solution, preserve at packing ， – 20 DEG C after mixing.
4, serial standards concentration is selected to be 0,0.15 by experiment, 0.6,1.7,3.3,8.3,20 μ g/L.
5, other components of reagent preparation box: 20 times of concentrated cleaning solutions (the 0.02M phosphate buffer containing 0.05% Tween-20, pH=7.4), sample diluting liquid (calf serum of deactivation), chemical luminous substrate A, B liquid are respectively luminol solution, hydrogen peroxide and special efficacy reinforcing agent (to iodophenol) solution thereof.
6, the accuracy of the method generate a reagent box, sensitivity, precision and qualified stability is identified.
7, according to the requirement of kit by these component packing in the vial, finished product is assembled into.
the using method of embodiment 2 kit of the present invention:
1, in 4 DEG C of refrigerators, take out kit, equilibrium at room temperature 20 minutes, get one bottle of concentrated washing lotion, adding distil water (1ml+19ml) is for subsequent use.
2, luminous plaque is taken out from sealing bag, the anti-fPSA antibody-solutions (1:2000) that 100 μ L FITC mark is joined in the ELISA Plate being coated with anti-FITC antibody, incubation 1 hour at 37 DEG C.
3, discard liquid in each hole, cleansing solution is filled each hole, leave standstill 10-20 second, get rid of cleansing solution; Repeat to wash plate, finally pat dry on clean thieving paper.
4, establish each 2 holes of serial standards concentration, each sample well 2 hole, get standard items or each 50 μ l of sample solution in corresponding plate hole, add enzyme marker 50 μ l again, micro oscillator fully vibrates mixing, with adhesive sticker sheet capping reaction plate, then puts reaction plate 37 DEG C of incubations 30 minutes.
5, carefully get rid of dereaction liquid, then wash five subsynchronous rapid 3.
6, after using first 5 minutes and being mixed with B liquid 100:1 by luminous substrate A liquid, in every hole, add 50 μ L chemical luminous substrates successively, room temperature lucifuge is measured luminous intensity after reacting 10 minutes.
7, with RLU value, fPSA concentration is mapped with log-log coordinate, by typical curve, quantitative test is realized to fPSA in Sample serum.
The advantage that the present invention has:
Result high specificity, highly sensitive, stable, convenient etc.The present invention is easy and simple to handle, and required detecting instrument (Chemiluminescence Apparatus) generally uses at various big hospital and inspection center.
Claims (1)
1. prepare a method for free prostate gland specificity antigen (fPSA) chemical luminescence immune analysis diagnosis reagent kit, comprise the following steps:
1) with anti-FITC antibody bag by solid phase carrier, obtain the solid phase carrier of anti-FITC antibody bag quilt;
2) mark anti-PSA antibody by following step FITC, obtain the anti-PSA antibody of FITC mark:
(I) Na that PSA antibody 1 mg puts 50 mM pH 9.3 is got
2cO
3-NaHCO
34 DEG C of dialysis 24 h in damping fluid, last fixing fabric structure is within 200 μ l;
(II) Na that FITC 2 mg is dissolved in 1 ml 50 mM pH 9.3 is got
2cO
3-NaHCO
3in damping fluid;
(III) liquid obtained in above-mentioned steps (I) is placed in magnetic stirring apparatus, getting the liquid 25 μ l obtained in above-mentioned steps (II) slowly drops in A liquid, added between 5-8 minute, prevent bubble, then put 4 DEG C and stir 12-16 hour;
(IV) reactant liquor is taken out the centrifugation 20 minutes in 10000 revs/min, removing microprecipitation thing, supernatant dress bag filter, puts in the PBS solution of 10 mM pH=7.4 and dialyses 4 days, change dislysate every day 2 times;
(V) centrifugally remove sediment, label is diluted to 1 ml, adds appropriate NaN
3, packing, preserves at-20 DEG C;
3) by following step enzyme labeling anti-fPSA antibody, the anti-fPSA antibody of enzyme labeling is obtained:
I () takes 2mgHRP and is dissolved in 1ml distilled water;
(ii) NaIO of the 0.1mol/L that 200 μ l newly configure is added
4solution, stirs 20 minutes in room temperature gently, and solution is brown-green;
(iii) by sodium acetate buffer dialysed overnight at 4 DEG C of the 0.001mol/L of pH=4.4;
(iv) 20 μ l 0.2mol/L Na are added
2cO
3damping fluid, makes pH value of solution be promoted to 9.0-9.5;
V fPSA antibody is deployed into the concentration of 8mg/ml with the carbonate buffer solution of 0.01mol/L, pH=9.5 by (), and slowly added by antibody-solutions in isopyknic above-mentioned HRP solution, stirring at room temperature 2 hours;
(vi) add the dobell's solution of the 4mg/ml of fresh configuration, be placed in 4 DEG C 2 hours;
(vii) in 4 DEG C, dialyse 24 hours in the sodium borate buffer liquid of 0.1 mol/L, exchange buffering liquid 3 times therebetween;
(viii) add equivalent 60% neutral glycerine solution, preserve at packing ， – 20 DEG C after mixing;
4) the anti-PSA antibody of the FITC mark of the above-mentioned acquisition of packing, the anti-fPSA antibody of enzyme labeling and this enzyme act on chemical luminous substrate, series concentration standard items;
5) finished product is assembled into.
2. the method for claim 1, is characterized in that, wraps by solid phase carrier by the following method:
1) mixing wrapping to be added to anti-FITC antibody in the citrate buffer solution of pH=4.4 ~ 5.0, then using gained mixed liquor bag by solid phase carrier;
2) coated solid phase carrier is washed;
3) bovine serum albumin(BSA) is used to close the above-mentioned carrier through washing.
3. method as claimed in claim 2, it is characterized in that, the pH value of described citrate buffer solution is 4.8.
4. method as claimed in claim 1 or 2, it is characterized in that, described solid phase carrier is microwell plate, plastic bead, plastic tube or magnetic-particle.
5. the method for claim 1, is characterized in that, described chemical luminous substrate is 1,2-dichloroethane analog derivative, luminol or different luminol.
6. method as claimed in claim 5, it is characterized in that, described 1,2-dichloroethane analog derivative is (diamantane)-1,2-dichloroethane, 3-(2 '-spiral diamantane)-4-methoxyl-4-(3 "-phosphorus acyloxy) phenyl-1,2-dichloroethane, CSPD or CDP-Star.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210291449.9A CN102818892B (en) | 2012-08-16 | 2012-08-16 | Detection kit for prostate specific antigen and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210291449.9A CN102818892B (en) | 2012-08-16 | 2012-08-16 | Detection kit for prostate specific antigen and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102818892A CN102818892A (en) | 2012-12-12 |
| CN102818892B true CN102818892B (en) | 2015-02-18 |
Family
ID=47303131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210291449.9A Active CN102818892B (en) | 2012-08-16 | 2012-08-16 | Detection kit for prostate specific antigen and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102818892B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA030682B1 (en) | 2012-03-05 | 2018-09-28 | Ой Арктик Партнерс Аб | METHODS AND DEVICES FOR PREDICTING THE RISK OF PROSTATE CANCER AND VOLUME OF THE PROSTATE |
| CN103033611A (en) * | 2012-12-13 | 2013-04-10 | 北京新华联协和药业有限责任公司 | Chemiluminiscence diagnostic kit for sensitization allergens and preparation method thereof |
| CN103087171B (en) * | 2012-12-24 | 2015-01-14 | 中国人民解放军第四军医大学 | anti-PSMA/FITC bispecific antibody for early diagnosis and treatment of prostate cancer and preparation method thereof |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| JP6775488B2 (en) | 2014-03-28 | 2020-10-28 | オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ | Compositions and Methods Related to Diagnosis of Prostate Cancer |
| US11921115B2 (en) * | 2015-03-27 | 2024-03-05 | Opko Diagnostics, Llc | Prostate antigen standards and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180417B1 (en) * | 1999-04-22 | 2001-01-30 | Bayer Corporation | Immunochromatographic assay |
| CN1880958A (en) * | 2005-06-14 | 2006-12-20 | 郑州安图绿科生物工程有限公司 | Enzyme-catalyzed chemiluminescence immune detection system |
| CN101377490B (en) * | 2007-08-30 | 2012-07-04 | 北京科美生物技术有限公司 | Magnetic microparticle separating chemiluminescence immune analysis determination reagent kit for detecting related sign object and preparing method thereof |
| CN101377500A (en) * | 2007-08-31 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Free prostate gland specificity antigen chemiluminescence immune analysis determination reagent kit and preparing method thereof |
| CN101377515A (en) * | 2008-04-16 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Thyrotropin chemiluminescence immune analysis determination reagent kit and preparing method thereof |
| CN101377504A (en) * | 2008-04-16 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Chemiluminescence immune analysis determination reagent kit for detecting Toxoplasma Gondi IgM antibody |
| CN101661036A (en) * | 2009-08-27 | 2010-03-03 | 北京倍爱康生物技术有限公司 | Aflatoxin B1 magnetic particle separation enzyme-linked immunoassay |
| CN101907627A (en) * | 2010-08-05 | 2010-12-08 | 北京倍爱康生物技术有限公司 | Clenbuterol hydrochloride magnetic particle separation enzyme-linked immunosorbent assay method |
-
2012
- 2012-08-16 CN CN201210291449.9A patent/CN102818892B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102818892A (en) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102818892B (en) | Detection kit for prostate specific antigen and preparation method thereof | |
| CN102072957B (en) | Hepatitis C virus antibody diagnostic kit and preparation method thereof | |
| CN105785043B (en) | For quantitatively detecting AFP L3% kit | |
| CN101363860A (en) | Syphilis helicoid antibody chemiluminescence immune assay determination kit and method for preparing same | |
| CN101377500A (en) | Free prostate gland specificity antigen chemiluminescence immune analysis determination reagent kit and preparing method thereof | |
| CN107543932A (en) | The magnetic microparticle chemiluminescence detection kit and preparation method of a kind of calcitonin | |
| CN101377504A (en) | Chemiluminescence immune analysis determination reagent kit for detecting Toxoplasma Gondi IgM antibody | |
| CN101533028A (en) | Chemoluminescent immunoassay kit of hyaluronic acid and preparation method thereof | |
| CN101377505A (en) | Des-gamma-carboxy-pro-thrombin microplate chemiluminescence immune analysis determination reagent kit and preparing method thereof | |
| CN103033624A (en) | Human myeloperoxidase chemiluminescent immunodetection kit | |
| CN101368969A (en) | Chemical luminescence immune analysis quantitative measuring reagent kit for IV type collagen and preparation method thereof | |
| CN102081100B (en) | Liver cancer multi-marker micro-array kit as well as preparation method and application thereof | |
| CN101363861A (en) | Hepatitis b virus surface antigen chemiluminescence immune assay determination kit and method for preparing same | |
| CN101329343A (en) | New generation early diagnosis prostate gland cancer reagent kit and preparation method and detection process thereof | |
| CN101539576A (en) | Hepatitis B virus pre S1 antigen chemiluminscence immunoassay kit and preparation method thereof | |
| CN101377498A (en) | Prostate gland specificity antigen chemiluminescence immune analysis determination reagent kit and preparing method thereof | |
| CN102798726A (en) | Quantitative determination kit of chemiluminescence immunoassay for Vitamin B12 (VB 12) and preparation method thereof | |
| CN102749456B (en) | Kit for chemilumineseent quantitative immunoassay of angiotensin I and preparation method thereof | |
| CN101571544A (en) | Islet cell antibody chemiluminescence immunoassay kit and preparation method thereof | |
| CN101178404B (en) | Human immunodeficiency virus antibody chemiluminescence immune analyzing diagnose reagent box and method of producing the same | |
| CN109425740A (en) | Abnormal prothrombin (PIVKA- II) magnetic microparticle chemiluminescence immune assay determination kit and preparation method thereof | |
| CN101545911A (en) | Chemoluminescence immunoassay quantitative measuring kit of cytokeratin 18 and preparation method thereof | |
| CN101551395A (en) | Chemiluminescence immunoassay kit of hepatitis E virus IgM antibody and preparation method thereof | |
| CN101545910A (en) | Ferritin chemoluminescence immunoassay quantitative measuring kit and preparation method thereof | |
| CN102183636A (en) | Diagnostic kit for anti-strep-A DNase B antibody with chemiluminescence immunoassay and using method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Lepu (Beijing) Diagnostic Technology Co.,Ltd. Document name: Notification that Application Deemed not to be Proposed |
|
| DD01 | Delivery of document by public notice | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 102200 the 3 floor of the 4 production building, No. 5, Chao Qian Road, Changping District science and Technology Park, Beijing. Patentee after: Lepu (Beijing) Diagnostic Technology Co.,Ltd. Address before: 102200 the 3 floor of the 4 production building, No. 5, Chao Qian Road, Changping District science and Technology Park, Beijing. Patentee before: Beijing Hongji Polytron Technologies Inc. and biological |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP03 | Change of name, title or address |
Address after: 102200 the 3 floor of the 4 production building, No. 5, Chao Qian Road, Changping District science and Technology Park, Beijing. Patentee after: Beijing Hongji Polytron Technologies Inc. and biological Address before: 100083 room 1801, Xue Hun 16, Xue Qing Road, Haidian District, Beijing. Patentee before: BEIJING ENJIHE BIOTECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address |